Marillion Pharmaceuticals Initiates Clinical Development of Novel Anticancer Drug
MALVERN, Pa.--(BUSINESS WIRE)--Marillion Pharmaceuticals, Inc., a privately-held development-stage pharmaceutical company focused on novel therapeutics for the treatment of cancer, inflammatory and autoimmune diseases, announced today that its investigational new drug application (IND) has been cleared by the FDA. Marillion is now able to proceed with its planned Phase 1 human clinical trial for the company’s lead product candidate, MN-201, an orally administered vitamin D5 analog for the treatment of cancer.